FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Peter Houghton

Research Profile

Living Beings

Chemicals & Drugs

Disorders

Anatomy

Procedures

Concepts & Ideas

Drug Dose Response Relationship

Physiology

Drug Resistance

Co-author Network

Publications

TOP 3
Stephen T Keir; E Anders Kolb; Raushan T Kurmasheva; Richard Lock; John M Maris; Christopher L Morton; C Patrick Reynolds; Hernan Carol; Richard Gorlick; Peter J Houghton; Min H Kang; Jianrong Wu; Malcolm A Smith
Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program.
C Patrick Reynolds; Catherine A Billups; Hernan Carol; Richard Gorlick; Peter J Houghton; Min H Kang; Stephen T Keir; E Anders Kolb; Raushan T Kurmasheva; Richard Lock; John M Maris; Malcolm A Smith
Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program.
Hernan Carol; Kathryn Evans; Peter J Houghton; Malcolm A Smith; B Szymanska; Ingrid Boehm; Richard B Lock
The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Peter Houghton (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Stephen T Keir; E Anders Kolb; Raushan T Kurmasheva; Richard Lock; John M Maris; Christopher L Morton; C Patrick Reynolds; Hernan Carol; Richard Gorlick; Peter J Houghton; Min H Kang; Jianrong Wu; Malcolm A Smith
Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program.
Pediatric blood & cancer 2013;60(5):783-90.
2013: C Patrick Reynolds; Catherine A Billups; Hernan Carol; Richard Gorlick; Peter J Houghton; Min H Kang; Stephen T Keir; E Anders Kolb; Raushan T Kurmasheva; Richard Lock; John M Maris; Malcolm A Smith
Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program.
Pediatric blood & cancer 2013;60(5):791-8.
2013: Hernan Carol; Kathryn Evans; Peter J Houghton; Malcolm A Smith; B Szymanska; Ingrid Boehm; Richard B Lock
The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2013;19(7):1795-805.
2013: Hernan Carol; Brian Geier; Richard Gorlick; Peter J Houghton; Min H Kang; Stephen T Keir; E Anders Kolb; Raushan T Kurmasheva; John M Maris; C Patrick Reynolds; Malcolm A Smith; Catherine A Billups; Richard B Lock
Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program.
Pediatric blood & cancer 2013;60(4):633-41.
2012: Richard Gorlick; Peter J Houghton; Min H Kang; Stephen T Keir; E Anders Kolb; Richard Lock; John M Maris; Christopher L Morton; Geoffrey Neale; Doris Phelps; C Patrick Reynolds; Catherine A Billups; Hernan Carol; Malcolm A Smith
Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program.
Pediatric blood & cancer 2012;59(7):1266-74.
2012: Malcolm A Smith; Jeffrey A Toretsky; Denise Alexander; Catherine A Billups; Min H Kang; Raushan T Kurmasheva; C Patrick Reynolds; Peter J Houghton
Evaluation of arsenic trioxide by the pediatric preclinical testing program with a focus on Ewing sarcoma.
Pediatric blood & cancer 2012;59(4):753-5.
2012: Stephen T Keir; Raushan T Kurmasheva; Christopher L Morton; Peter J Houghton; Jianrong Wu; Malcolm A Smith
Initial testing of the multitargeted kinase inhibitor pazopanib by the Pediatric Preclinical Testing Program.
Pediatric blood & cancer 2012;59(3):586-8.
2012: Richard Gorlick; Peter J Houghton; Min H Kang; Stephen T Keir; E Anders Kolb; Raushan T Kurmasheva; Richard Lock; John M Maris; C Patrick Reynolds; Catherine A Billups; Hernan Carol; Malcolm A Smith
Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program.
Pediatric blood & cancer 2012;59(3):518-24.
2012: Malcolm A Smith; Peter G Smith; Jianrong Wu; Jie Yu; Min H Kang; Stephen T Keir; E Anders Kolb; Richard Lock; John M Maris; Christopher L Morton; C Patrick Reynolds; Hernan Carol; Richard Gorlick; Peter J Houghton
Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program.
Pediatric blood & cancer 2012;59(2):246-53.
2012: Malcolm A Smith; Janine Arts; Tarig Bashir; Hernan Carol; Richard Gorlick; Michel Janicot; Min H Kang; Stephen T Keir; E Anders Kolb; Raushan T Kurmasheva; Richard Lock; John M Maris; Christopher L Morton; C Patrick Reynolds; Peter J Houghton
Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program.
Pediatric blood & cancer 2012;59(2):329-32.
2012: Wayne L Furman; Dana Hawkins; Peter J Houghton; Sandy Kovach; M Beth McCarville; Lisa M McGregor; Valerie McPherson; Mihaela Onciu; Catherine A Billups; Andrew M Davidoff; Clinton F Stewart; Jianrong Wu; Victor M Santana
A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma.
Investigational new drugs 2012;30(4):1660-70.
2012: Min H Kang; Stephen T Keir; E Anders Kolb; Richard Lock; John M Maris; Christopher L Morton; C Patrick Reynolds; Denise Alexander; Hernan Carol; Richard Gorlick; Peter J Houghton; Amy Wozniak; Malcolm A Smith
Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program.
Pediatric blood & cancer 2012;59(1):185-8.
2012: Richard B Lock; John M Maris; Christopher L Morton; C Patrick Reynolds; Hernan Carol; Richard Gorlick; Peter J Houghton; Min H Kang; Stephen T Keir; E Anders Kolb; Amy W Wozniak; Malcolm A Smith
Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program.
Pediatric blood & cancer 2012;58(6):916-23.
2012: E Anders Kolb; Raushan T Kurmasheva; Richard Lock; John M Maris; C Patrick Reynolds; Hernan Carol; Richard Gorlick; Peter J Houghton; Min H Kang; Stephen T Keir; Jianrong Wu; Malcolm A Smith
Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling.
Pediatric blood & cancer 2012;58(5):815-8.
2012: Peter J Houghton; Min H Kang; Stephen T Keir; E Anders Kolb; Richard Lock; John M Maris; Christopher L Morton; C Patrick Reynolds; Catherine A Billups; Hernan Carol; Richard Gorlick; Malcolm A Smith
Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program.
Pediatric blood & cancer 2012;58(4):636-9.
2012: Christopher L Morton; Malcolm A Smith; Jianrong Wu; Catherine A Billups; Richard Gorlick; Stephen T Keir; E Anders Kolb; John M Maris; Peter J Houghton
Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program.
Pediatric blood & cancer 2012;58(4):566-71.
2012: Hemant K Bid; Raushan T Kurmasheva; Doris A Phelps; Jun Zhan; Peter J Houghton
Potent inhibition of angiogenesis by the IGF-1 receptor-targeting antibody SCH717454 is reversed by IGF-2.
Molecular cancer therapeutics 2012;11(3):649-59.
2012: Hemant K Bid; Chenglong Li; Jiayuh Lin; Cheryl A London; Duane Oswald; Peter J Houghton
Anti-angiogenic activity of a small molecule STAT3 inhibitor LLL12.
PloS one 2012;7(4):e35513.
2011: Charles Patrick Reynolds; Malcolm A Smith; Catherine A Billups; Hernan Carol; Richard Gorlick; Min H Kang; Stephen T Keir; E Anders Kolb; Richard Lock; John M Maris; Christopher L Morton; Peter J Houghton
Initial testing of lenalidomide by the pediatric preclinical testing program.
Pediatric blood & cancer 2011;57(4):606-11.
2011: Yoshiki Katsumi; Ken Kikuchi; Hiroshi Kuroda; Yasumichi Kuwahara; Mitsuru Miyachi; Tohru Sugimoto; Shinichi Tamura; Satoko Tsubai-Shimizu; Kunihiko Tsuchiya; Shigeki Yagyu; Peter J Houghton; Tomoko Iehara; Hajime Hosoi
Sensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is inversely correlated with p16 expression.
Biochemical and biophysical research communications 2011;413(1):62-8.
2011: Peter J Houghton; Min H Kang; Stephen T Keir; E Anders Kolb; Richard Lock; John M Maris; Christopher L Morton; Doris Phelps; Charles Patrick Reynolds; Hernan Carol; Richard Gorlick; Yongchuan Gu; William R Wilson; Amy W Wozniak; Malcolm A Smith
Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program.
Pediatric blood & cancer 2011;57(3):443-53.
2011: Shripad V Bhagwat; Mark Bittner; Andy Cooke; Andrew P A Crew; Lorina Dudkin; David M Epstein; Neil W Gibson; Prafulla C Gokhale; Peter J Houghton; Jennifer Kahler; Christine Mantis; Robert Wild; Jennifer Workman; Yan Yao; Lee D Arnold; Jonathan A Pachter
Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin.
Molecular cancer therapeutics 2011;10(8):1394-406.
2011: Malcolm A Smith; Hernan Carol; Richard Gorlick; Min H Kang; Stephen T Keir; E Anders Kolb; Richard Lock; John M Maris; Christopher L Morton; Charles Patrick Reynolds; Peter J Houghton
Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program.
Pediatric blood & cancer 2011;57(2):268-74.
2011: Hakan Cam; Peter J Houghton
Regulation of mammalian target of rapamycin complex 1 (mTORC1) by hypoxia: causes and consequences.
Targeted oncology 2011;6(2):95-102.
2011: Hemant K Bid; Peter J Houghton
Targeting angiogenesis in childhood sarcomas.
Sarcoma 2011;2011():601514.
2010: Hernan Carol; Christopher L Morton; Richard Gorlick; E Anders Kolb; Stephen T Keir; Charles Patrick Reynolds; Min H Kang; John M Maris; Catherine Billups; Malcolm A Smith; Peter J Houghton; Richard B Lock
Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program.
Pediatric blood & cancer 2010;55(7):1329-37.
2010: Peter J Houghton; Christopher L Morton; Min Kang; Charles Patrick Reynolds; Catherine A Billups; Edward Favours; Debbie Payne-Turner; Chandra Tucker; Malcolm A Smith
Evaluation of cytarabine against Ewing sarcoma xenografts by the pediatric preclinical testing program.
Pediatric blood & cancer 2010;55(6):1224-6.
2010: Hakan Cam; John B Easton; Anthony High; Peter J Houghton
mTORC1 signaling under hypoxic conditions is controlled by ATM-dependent phosphorylation of HIF-1α.
Molecular cell 2010;40(4):509-20.
2010: Christopher L Morton; Peter J Houghton; E Anders Kolb; Richard Gorlick; Charles Patrick Reynolds; Min H Kang; John M Maris; Stephen T Keir; Jianrong Wu; Malcolm A Smith
Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program.
Pediatric blood & cancer 2010;55(2):295-303.
2010: Peter J Houghton; Christopher L Morton; Richard Gorlick; E Anders Kolb; Stephen T Keir; Charles Patrick Reynolds; Min H Kang; John M Maris; Jianrong Wu; Malcolm A Smith
Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program.
Pediatric blood & cancer 2010;54(7):921-6.
2010: Hernan Carol; Peter J Houghton; Christopher L Morton; E Anders Kolb; Richard Gorlick; Charles Patrick Reynolds; Min H Kang; John M Maris; Stephen T Keir; Amy Watkins; Malcolm A Smith; Richard B Lock
Initial testing of topotecan by the pediatric preclinical testing program.
Pediatric blood & cancer 2010;54(5):707-15.
2010: Malcolm A Smith; Christopher L Morton; E Anders Kolb; Richard Gorlick; Stephen T Keir; Hernan Carol; Richard Lock; Min H Kang; Charles Patrick Reynolds; John M Maris; Amy E Watkins; Peter J Houghton
Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program.
Pediatric blood & cancer 2010;54(2):307-10.
2010: Jianrong Wu; Peter J Houghton
Interval approach to assessing antitumor activity for tumor xenograft studies.
Pharmaceutical statistics 2010;9(1):46-54.
2009: Hernan Carol; Richard Lock; Peter J Houghton; Christopher L Morton; E Anders Kolb; Richard Gorlick; Charles Patrick Reynolds; John M Maris; Stephen T Keir; Catherine A Billups; Malcolm A Smith
Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program.
Pediatric blood & cancer 2009;53(7):1255-63.
2009: Raushan T Kurmasheva; Lorina Dudkin; Catherine Billups; Larisa V Debelenko; Christopher L Morton; Peter J Houghton
The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma.
Cancer research 2009;69(19):7662-71.
2009: Richard Gorlick; E Anders Kolb; Peter J Houghton; Christopher L Morton; Doris Phelps; Paula Schaiquevich; Clinton Stewart; Stephen T Keir; Richard Lock; Hernan Carol; Charles Patrick Reynolds; John M Maris; Jianrong Wu; Malcolm A Smith
Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program.
Pediatric blood & cancer 2009;53(4):594-8.
2009: Wayne L Furman; Fariba Navid; Najat C Daw; M Beth McCarville; Lisa M McGregor; Sheri L Spunt; Carlos Rodriguez-Galindo; John C Panetta; Kristine R Crews; Jianrong Wu; Amar Gajjar; Peter J Houghton; Victor M Santana; Clinton F Stewart
Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(27):4599-604.
2009: Jianrong Wu; Peter J Houghton
Assessing cytotoxic treatment effects in preclinical tumor xenograft models.
Journal of biopharmaceutical statistics 2009;19(5):755-62.
2009: Lili Shu; Peter J Houghton
The mTORC2 complex regulates terminal differentiation of C2C12 myoblasts.
Molecular and cellular biology 2009;29(17):4691-700.
2009: Christopher L Morton; Peter J Houghton; Richard Gorlick; E Anders Kolb; Richard Lock; Hernan Carol; Stephen T Keir; Charles Patrick Reynolds; Min H Kang; John M Maris; Catherine A Billups; Malcolm A Smith
Initial testing of aplidin by the pediatric pre-clinical testing program.
Pediatric blood & cancer 2009;53(3):509-12.
2009: Teneille Walker; Clint Mitchell; Margaret A Park; Adly Yacoub; Martin Graf; Mohamed Rahmani; Peter J Houghton; Christina Voelkel Johnson; Steven Grant; Paul Dent
Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms.
Molecular pharmacology 2009;76(2):342-55.
2009: Peter J Houghton
How do we identify novel treatment for childhood cancer?
Pediatric blood & cancer 2009;52(3):310-1.
2008: Geoffrey Neale; Xiaoping Su; Christopher L Morton; Doris Phelps; Richard Gorlick; Richard B Lock; Charles Patrick Reynolds; John M Maris; Henry S Friedman; Jeffrey S Dome; Joseph Khoury; Timothy Triche; Robert C Seeger; Richard J Gilbertson; Javed Khan; Malcolm A Smith; Peter J Houghton
Molecular characterization of the pediatric preclinical testing panel.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(14):4572-83.
2008: John M Maris; Joshua Courtright; Peter J Houghton; Christopher L Morton; E Anders Kolb; Richard Lock; Mayamin Tajbakhsh; Charles Patrick Reynolds; Stephen T Keir; Jianrong Wu; Malcolm A Smith
Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program.
Pediatric blood & cancer 2008;51(1):42-8.
2008: Malcolm A Smith; Christopher L Morton; Doris A Phelps; E Anders Kolb; Richard Lock; Hernan Carol; Charles Patrick Reynolds; John M Maris; Stephen T Keir; Jianrong Wu; Peter J Houghton
Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program.
Pediatric blood & cancer 2008;51(1):34-41.
2008: E Anders Kolb; Richard Gorlick; Peter J Houghton; Christopher L Morton; Richard Lock; Hernan Carol; Charles Patrick Reynolds; John M Maris; Stephen T Keir; Catherine A Billups; Malcolm A Smith
Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program.
Pediatric blood & cancer 2008;50(6):1190-7.
2008: Richard Lock; Hernan Carol; Peter J Houghton; Christopher L Morton; E Anders Kolb; Richard Gorlick; Charles Patrick Reynolds; John M Maris; Stephen T Keir; Jianrong Wu; Malcolm A Smith
Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program.
Pediatric blood & cancer 2008;50(6):1181-9.
2008: E Anders Kolb; Richard Gorlick; Peter J Houghton; Christopher L Morton; Richard B Lock; Mayamin Tajbakhsh; Charles Patrick Reynolds; John M Maris; Stephen T Keir; Catherine A Billups; Malcolm A Smith
Initial testing of dasatinib by the pediatric preclinical testing program.
Pediatric blood & cancer 2008;50(6):1198-206.
2008: Mimi Tajbakhsh; Peter J Houghton; Christopher L Morton; E Anders Kolb; Richard Gorlick; John M Maris; Stephen T Keir; Jianrong Wu; Charles Patrick Reynolds; Malcolm A Smith; Richard B Lock
Initial testing of cisplatin by the pediatric preclinical testing program.
Pediatric blood & cancer 2008;50(5):992-1000.
2008: Peter J Houghton; Christopher L Morton; E Anders Kolb; Richard Gorlick; Richard Lock; Hernan Carol; Charles Patrick Reynolds; John M Maris; Stephen T Keir; Catherine A Billups; Malcolm A Smith
Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program.
Pediatric blood & cancer 2008;50(4):799-805.
2008: Monika Wierdl; Lyudmila Tsurkan; Janice L Hyatt; Carol C Edwards; M Jason Hatfield; Christopher L Morton; Peter J Houghton; Mary K Danks; Matthew R Redinbo; Philip Potter
An improved human carboxylesterase for enzyme/prodrug therapy with CPT-11.
Cancer gene therapy 2008;15(3):183-92.
2008: John M Maris; Joshua Courtright; Peter J Houghton; Christopher L Morton; Richard Gorlick; E Anders Kolb; Richard Lock; Mayamin Tajbakhsh; Charles Patrick Reynolds; Stephen T Keir; Jianrong Wu; Malcolm A Smith
Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program.
Pediatric blood & cancer 2008;50(3):581-7.
2008: Franklin C Harwood; Lili Shu; Peter J Houghton
mTORC1 signaling can regulate growth factor activation of p44/42 mitogen-activated protein kinases through protein phosphatase 2A.
The Journal of biological chemistry 2008;283(5):2575-85.
2008: Peter J Houghton; Christopher L Morton; E Anders Kolb; Richard Lock; Hernan Carol; Charles Patrick Reynolds; Nino Keshelava; John M Maris; Stephen T Keir; Jianrong Wu; Malcolm A Smith
Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program.
Pediatric blood & cancer 2008;50(1):37-45.
2007: Christopher L Morton; Rachel A Papa; Richard B Lock; Peter J Houghton
Preclinical chemotherapeutic tumor models of common childhood cancers: solid tumors, acute lymphoblastic leukemia, and disseminated neuroblastoma.
Current protocols in pharmacology / editorial board, S.J. Enna (editor-in-chief) ... [et al.] 2007;Chapter 14():Unit14.8.
2007: Peter J Houghton; Christopher L Morton; Chandra Tucker; Debbie Payne; Edward Favours; Claire Cole; Richard Gorlick; E Anders Kolb; Wendong Zhang; Richard Lock; Hernan Carol; Mimi Tajbakhsh; Charles Patrick Reynolds; John M Maris; Joshua Courtright; Stephen T Keir; Henry S Friedman; Charles Stopford; Joseph Zeidner; Jianrong Wu; Tiebin Liu; Catherine A Billups; Javed Khan; Sherry Ansher; Jian Zhang; Malcolm A Smith
The pediatric preclinical testing program: description of models and early testing results.
Pediatric blood & cancer 2007;49(7):928-40.
2007: Maryam Fouladi; Fred H Laningham; Jianrong Wu; Melinda A O'Shaughnessy; Kristen Molina; Alberto Broniscer; Sheri L Spunt; Inga Luckett; Clinton F Stewart; Peter J Houghton; Richard J Gilbertson; Wayne L Furman
Phase I study of everolimus in pediatric patients with refractory solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(30):4806-12.
2007: Raushan T Kurmasheva; Peter J Houghton
Pediatric oncology.
Current opinion in chemical biology 2007;11(4):424-32.
2007: Christopher L Morton; Edward Favours; Kimberly S Mercer; Claire R Boltz; Jeri Carol Crumpton; Chandra Tucker; Catherine A Billups; Peter J Houghton
Evaluation of ABT-751 against childhood cancer models in vivo.
Investigational new drugs 2007;25(4):285-95.
2007: Raushan T Kurmasheva; Franklin C Harwood; Peter J Houghton
Differential regulation of vascular endothelial growth factor by Akt and mammalian target of rapamycin inhibitors in cell lines derived from childhood solid tumors.
Molecular cancer therapeutics 2007;6(5):1620-8.
2007: Jun Zhan; John B Easton; Shile Huang; Ashutosh Mishra; Limin Xiao; Eilyn R Lacy; Richard W Kriwacki; Peter J Houghton
Negative regulation of ASK1 by p21Cip1 involves a small domain that includes Serine 98 that is phosphorylated by ASK1 in vivo.
Molecular and cellular biology 2007;27(9):3530-41.
2007: Christopher L Morton; Peter J Houghton
Establishment of human tumor xenografts in immunodeficient mice.
Nature protocols 2007;2(2):247-50.
2006: Raushan T Kurmasheva; Shile Huang; Peter J Houghton
Predicted mechanisms of resistance to mTOR inhibitors.
British journal of cancer 2006;95(8):955-60.
2006: Maryam Fouladi; Wayne L Furman; Thomas Chin; Burgess B Freeman; Lorina Dudkin; Clinton F Stewart; Mark Krailo; Rose Anne Speights; Ashish Ingle; Peter J Houghton; John Wright; Peter Charles Adamson; Susan M Blaney
Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(22):3678-85.
2006: Raushan T Kurmasheva; Peter J Houghton
IGF-I mediated survival pathways in normal and malignant cells.
Biochimica et biophysica acta 2006;1766(1):1-22.
2006: Markos Leggas; John C Panetta; Yanli Zhuang; John D Schuetz; Brad Johnston; Feng Bai; Brian P Sorrentino; Sheng Zhou; Peter J Houghton; Clinton F Stewart
Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo.
Cancer research 2006;66(9):4802-7.
2006: John B Easton; Raushan T Kurmasheva; Peter J Houghton
IRS-1: auditing the effectiveness of mTOR inhibitors.
Cancer cell 2006;9(3):153-5.
2006: Wayne L Furman; Kristine R Crews; Catherine A Billups; Jianrong Wu; Amar Gajjar; Najat C Daw; Christian C Patrick; Carlos Rodriguez-Galindo; Clinton F Stewart; Jeffrey S Dome; John C Panetta; Peter J Houghton; Victor M Santana
Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(4):563-70.
2006: Alberto Broniscer; Murali Chintagumpala; Maryam Fouladi; Matthew J Krasin; Mehmet Kocak; Daniel Bowers; Lisa C Iacono; Thomas E Merchant; Clinton F Stewart; Peter J Houghton; Larry E Kun; Davonna Ledet; Amar Gajjar
Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children.
Journal of neuro-oncology 2006;76(3):313-9.
2006: Claire Graham; Chandra Tucker; Jeremy Creech; Edward Favours; Catherine A Billups; Tiebin Liu; Maryam Fouladi; Burgess B Freeman; Clinton F Stewart; Peter J Houghton
Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(1):223-34.
2005: Christopher L Morton; Lisa Iacono; Janice L Hyatt; Kody R Taylor; Pamela J Cheshire; Peter J Houghton; Mary K Danks; Clinton F Stewart; Philip Potter
Activation and antitumor activity of CPT-11 in plasma esterase-deficient mice.
Cancer chemotherapy and pharmacology 2005;56(6):629-36.
2005: Jennifer K Peterson; Chandra Tucker; Edward Favours; Pamela J Cheshire; Jeremy Creech; Catherine A Billups; Richard A Smykla; Francis Y Lee; Peter J Houghton
In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(19 Pt 1):6950-8.
2005: Kuntebommanahalli N Thimmaiah; John B Easton; Glen S Germain; Christopher L Morton; Shantaram Kamath; John K Buolamwini; Peter J Houghton
Identification of N10-substituted phenoxazines as potent and specific inhibitors of Akt signaling.
The Journal of biological chemistry 2005;280(36):31924-35.
2005: Victor M Santana; Wayne L Furman; Catherine A Billups; Fredric A Hoffer; Andrew M Davidoff; Peter J Houghton; Clinton F Stewart
Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(18):4039-47.
2005: Michael H Woo; Jennifer K Peterson; Catherine A Billups; Hua Liang; Mary-Ann Bjornsti; Peter J Houghton
Enhanced antitumor activity of irofulven in combination with irinotecan in pediatric solid tumor xenograft models.
Cancer chemotherapy and pharmacology 2005;55(5):411-9.
2004: Clinton F Stewart; Markos Leggas; John D Schuetz; John C Panetta; Pamela J Cheshire; Jennifer Peterson; Najat C Daw; Jesse J Jenkins; Richard Gilbertson; Glen S Germain; Franklin C Harwood; Peter J Houghton
Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice.
Cancer research 2004;64(20):7491-9.
2004: Shile Huang; Lili Shu; John B Easton; Franklin C Harwood; Glen S Germain; Hidenori Ichijo; Peter J Houghton
Inhibition of mammalian target of rapamycin activates apoptosis signal-regulating kinase 1 signaling by suppressing protein phosphatase 5 activity.
The Journal of biological chemistry 2004;279(35):36490-6.
2004: Clinton F Stewart; Lisa C Iacono; Murali Chintagumpala; Stewart J Kellie; David Ashley; William C Zamboni; Mark N Kirstein; Maryam Fouladi; Louis G Seele; Dana Wallace; Peter J Houghton; Amar Gajjar
Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(16):3357-65.
2004: Mary-Ann Bjornsti; Peter J Houghton
Lost in translation: dysregulation of cap-dependent translation and cancer.
Cancer cell 2004;5(6):519-23.
2004: Mary-Ann Bjornsti; Peter J Houghton
The TOR pathway: a target for cancer therapy.
Nature reviews. Cancer 2004;4(5):335-48.
2004: J K Peterson; Peter J Houghton
Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development.
European journal of cancer (Oxford, England : 1990) 2004;40(6):837-44.
2004: Peter J Houghton; Glen S Germain; Franklin C Harwood; John D Schuetz; Clinton F Stewart; Elisabeth Buchdunger; Peter Traxler
Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro.
Cancer research 2004;64(7):2333-7.
2004: Najat C Daw; Victor M Santana; Lisa C Iacono; Wayne L Furman; Dana R Hawkins; Peter J Houghton; John C Panetta; Amar Gajjar; Clinton F Stewart
Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):829-37.
2004: Ravi Hegde; Padma Thimmaiah; Mayur C Yerigeri; Gowdahalli Krishnegowda; Kuntebommanahalli N Thimmaiah; Peter J Houghton
Anti-calmodulin acridone derivatives modulate vinblastine resistance in multidrug resistant (MDR) cancer cells.
European journal of medicinal chemistry 2004;39(2):161-77.
2004: Lars M Wagner; Kristine R Crews; Lisa C Iacono; Peter J Houghton; Christine E Fuller; M Beth McCarville; Robert E Goldsby; Karen H Albritton; Clinton F Stewart; Victor M Santana
Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(3):840-8.
2003: Shile Huang; Peter J Houghton
Targeting mTOR signaling for cancer therapy.
Current opinion in pharmacology 2003;3(4):371-7.
2003: Shile Huang; Lili Shu; Michael B Dilling; John B Easton; Franklin C Harwood; Hidenori Ichijo; Peter J Houghton
Sustained activation of the JNK cascade and rapamycin-induced apoptosis are suppressed by p53/p21(Cip1).
Molecular cell 2003;11(6):1491-501.
2003: Shile Huang; Mary-Ann Bjornsti; Peter J Houghton
Rapamycins: mechanism of action and cellular resistance.
Cancer biology & therapy 2003;2(3):222-32.
2003: Victor M Santana; William C Zamboni; Mark N Kirstein; Ming Tan; Tiebin Liu; Amar Gajjar; Peter J Houghton; Clinton F Stewart
A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(2):633-40.
2003: Kuntebommanahalli N Thimmaiah; John B Easton; Shile Huang; Karen A Veverka; Glen S Germain; Franklin C Harwood; Peter J Houghton
Insulin-like growth factor I-mediated protection from rapamycin-induced apoptosis is independent of Ras-Erk1-Erk2 and phosphatidylinositol 3'-kinase-Akt signaling pathways.
Cancer research 2003;63(2):364-74.
2002: Peter J Houghton; Peter Charles Adamson; Susan Blaney; Howard A Fine; Richard Gorlick; Michelle Haber; Lee Helman; Steve Hirschfeld; Melinda G Hollingshead; Mark Israel; Richard B Lock; John M Maris; Glenn Merlino; Wendy Patterson; Charles Patrick Reynolds; Kevin Shannon; Alice L Yu; John Yu; Malcolm A Smith
Testing of new agents in childhood cancer preclinical models: meeting summary.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(12):3646-57.
2002: Markos Leggas; Clinton F Stewart; Michael H Woo; Maryam Fouladi; Pamela J Cheshire; Jennifer K Peterson; Henry S Friedman; Catherine A Billups; Peter J Houghton
Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(9):3000-7.
2002: Lars M Wagner; Sylvie M Guichard; Rebecca A Burger; Christopher L Morton; Charles M Straign; Richard A Ashmun; Linda C Harris; Peter J Houghton; Philip Potter; Mary K Danks
Efficacy and toxicity of a virus-directed enzyme prodrug therapy purging method: preclinical assessment and application to bone marrow samples from neuroblastoma patients.
Cancer research 2002;62(17):5001-7.
2002: Xiongwen Zhang; Lili Shu; Hajime Hosoi; K Gopal Murti; Peter J Houghton
Predominant nuclear localization of mammalian target of rapamycin in normal and malignant cells in culture.
The Journal of biological chemistry 2002;277(31):28127-34.
2002: Gowdahalli Krishnegowda; Padma Thimmaiah; Ravi Hegde; Chhabil Dass; Peter J Houghton; Kuntebommanahalli N Thimmaiah
Synthesis and chemical characterization of 2-methoxy-N(10)-substituted acridones needed to reverse vinblastine resistance in multidrug resistant (MDR) cancer cells.
Bioorganic & medicinal chemistry 2002;10(7):2367-80.
2002: Lili Shu; Xiongwen Zhang; Peter J Houghton
Myogenic differentiation is dependent on both the kinase function and the N-terminal sequence of mammalian target of rapamycin.
The Journal of biological chemistry 2002;277(19):16726-32.
2002: Michael B Dilling; Glen S Germain; Lorina Dudkin; Arun L Jayaraman; Xiongwen Zhang; Franklin C Harwood; Peter J Houghton
4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin.
The Journal of biological chemistry 2002;277(16):13907-17.
2002: Shile Huang; Peter J Houghton
Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic.
Current opinion in investigational drugs (London, England : 2000) 2002;3(2):295-304.
2002: Peter J Houghton; Victor M Santana
Clinical trials using irinotecan.
Journal of pediatric hematology/oncology 2002;24(2):84-5.
2001: E J Yeoh; J M Cunningham; G C Yee; D Hunt; J A Houston; S L Richardson; Clinton F Stewart; Peter J Houghton; Laura C Bowman; Amar Gajjar
Topotecan-filgrastim combination is an effective regimen for mobilizing peripheral blood stem cells.
Bone marrow transplantation 2001;28(6):563-71.
2001: Lorina Dudkin; Michael B Dilling; Pamela J Cheshire; Franklin C Harwood; M Hollingshead; Arbuck Susan; R Travis; Edward A Sausville; Peter J Houghton
Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(6):1758-64.
2001: Shile Huang; LN Liu; Hajime Hosoi; Michael B Dilling; T Shikata; Peter J Houghton
p53/p21(CIP1) cooperate in enforcing rapamycin-induced G(1) arrest and determine the cellular response to rapamycin.
Cancer research 2001;61(8):3373-81.
2001: J Thompson; Sylvie M Guichard; Pamela J Cheshire; LB Richmond; CA Poquette; S T Ragsdale; B Webber; R Lorsbach; Mary K Danks; Peter J Houghton
Development, characterization and therapy of a disseminated model of childhood neuroblastoma in SCID mice.
Cancer chemotherapy and pharmacology 2001;47(3):211-21.
2001: Mark N Kirstein; Peter J Houghton; Pamela J Cheshire; LB Richmond; A K Smith; Suzan K Hanna; Clinton F Stewart
Relation between 9-aminocamptothecin systemic exposure and tumor response in human solid tumor xenografts.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(2):358-66.
2000: Peter J Houghton; Clinton F Stewart; Pamela J Cheshire; LB Richmond; Mark N Kirstein; CA Poquette; Ming Tan; Henry S Friedman; Thomas P Brent
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(10):4110-8.
2000: Carlos Rodriguez-Galindo; KM Radomski; Clinton F Stewart; Wayne L Furman; Victor M Santana; Peter J Houghton
Clinical use of topoisomerase I inhibitors in anticancer treatment.
Medical and pediatric oncology 2000;35(4):385-402.
2000: Alan C Taylor; Lili Shu; Mary K Danks; CA Poquette; Sheetal Shetty; Mathew J Thayer; Peter J Houghton; Linda C Harris
P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines.
Medical and pediatric oncology 2000;35(2):96-103.
2000: David S Middlemas; Clinton F Stewart; Mark N Kirstein; CA Poquette; Henry S Friedman; Peter J Houghton; Thomas P Brent
Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(3):998-1007.
2000: Margaret K Ma; William C Zamboni; KM Radomski; Wayne L Furman; Victor M Santana; Peter J Houghton; Suzan K Hanna; A K Smith; Clinton F Stewart
Pharmacokinetics of irinotecan and its metabolites SN-38 and APC in children with recurrent solid tumors after protracted low-dose irinotecan.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(3):813-9.
2000: C E M Gidding; Glen S Germain; Michael B Dilling; T G Meeuwsen-de Boer; Richard A Ashmun; Siebold S N de Graaf; K A Veverka; Willem A Kamps; Peter J Houghton
The influence of recombinant human insulin-like growth factor-I (rhIGF-I) on cell growth and cytotoxicity of drugs in childhood rhabdomyosarcoma cell lines and xenograft models.
Cancer chemotherapy and pharmacology 2000;45(1):21-30.
2000: Akiko Misawa; Hajime Hosoi; A Arimoto; T Shikata; S Akioka; T Matsumura; Peter J Houghton; Tadashi Sawada
N-Myc induction stimulated by insulin-like growth factor I through mitogen-activated protein kinase signaling pathway in human neuroblastoma cells.
Cancer research 2000;60(1):64-9.
1999: B C Channu; H N Kalpana; G B Eregowda; Chhabil Dass; Peter J Houghton; Kuntebommanahalli N Thimmaiah
Interaction of substituted phenoxazine chemosensitizers with bovine serum albumin.
Journal of pharmaceutical and biomedical analysis 1999;21(4):775-85.
1999: J Thompson; E O George; CA Poquette; Pamela J Cheshire; LB Richmond; S S de Graaf; M Ma; Clinton F Stewart; Peter J Houghton
Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(11):3617-31.
1999: Wayne L Furman; Clinton F Stewart; CA Poquette; Charles B Pratt; Victor M Santana; William C Zamboni; Laura C Bowman; Margaret K Ma; Fredric A Hoffer; William H Meyer; Alberto S Pappo; AW Walter; Peter J Houghton
Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(6):1815-24.
1999: Mary K Danks; Christopher L Morton; Erik J Krull; Pamela J Cheshire; LB Richmond; CW Naeve; CA Pawlik; Peter J Houghton; Philip Potter
Comparison of activation of CPT-11 by rabbit and human carboxylesterases for use in enzyme/prodrug therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(4):917-24.
1999: Hajime Hosoi; Michael B Dilling; T Shikata; LN Liu; Lili Shu; Richard A Ashmun; Glen S Germain; Robert T Abraham; Peter J Houghton
Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells.
Cancer research 1999;59(4):886-94.
1999: William C Zamboni; Laura C Bowman; Ming Tan; Victor M Santana; Peter J Houghton; William H Meyer; Charles B Pratt; Richard L Heideman; Amar Gajjar; A S Pappo; Clinton F Stewart
Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors.
Cancer chemotherapy and pharmacology 1999;43(6):454-60.
1999: William C Zamboni; Peter J Houghton; J L Hulstein; Mark N Kirstein; J Walsh; Pamela J Cheshire; Suzan K Hanna; Mary K Danks; Clinton F Stewart
Relationship between tumor extracellular fluid exposure to topotecan and tumor response in human neuroblastoma xenograft and cell lines.
Cancer chemotherapy and pharmacology 1999;43(4):269-76.
1998: Hajime Hosoi; Michael B Dilling; LN Liu; Mary K Danks; T Shikata; A Sekulic; Robert T Abraham; John C Lawrence; Peter J Houghton
Studies on the mechanism of resistance to rapamycin in human cancer cells.
Molecular pharmacology 1998;54(5):815-24.
1998: William C Zamboni; Amar Gajjar; T D Mandrell; S L Einhaus; Mary K Danks; W P Rogers; Richard L Heideman; Peter J Houghton; Clinton F Stewart
A four-hour topotecan infusion achieves cytotoxic exposure throughout the neuraxis in the nonhuman primate model: implications for treatment of children with metastatic medulloblastoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(10):2537-44.
1998: J Thompson; Clinton F Stewart; Peter J Houghton
Animal models for studying the action of topoisomerase I targeted drugs.
Biochimica et biophysica acta 1998;1400(1-3):301-19.
1998: LN Liu; P Dias; Peter J Houghton
Mutation of Thr115 in MyoD positively regulates function in murine fibroblasts and human rhabdomyosarcoma cells.
Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 1998;9(9):699-711.
1998: Peter J Houghton; Clinton F Stewart; J Thompson; V M Santana; Wayne L Furman; Henry S Friedman
Extending principles learned in model systems to clinical trials design.
Oncology (Williston Park, N.Y.) 1998;12(8 Suppl 6):84-93.
1998: CA Pawlik; Peter J Houghton; Clinton F Stewart; Pamela J Cheshire; LB Richmond; Mary K Danks
Effective schedules of exposure of medulloblastoma and rhabdomyosarcoma xenografts to topotecan correlate with in vitro assays.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(8):1995-2002.
1998: William C Zamboni; Clinton F Stewart; J Thompson; Victor M Santana; Pamela J Cheshire; LB Richmond; X Luo; CA Poquette; Janet A Houghton; Peter J Houghton
Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts.
Journal of the National Cancer Institute 1998;90(7):505-11.
1998: William C Zamboni; Amar Gajjar; Richard L Heideman; J H Beijnen; H Rosing; Peter J Houghton; Clinton F Stewart
Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(3):783-9.
1998: William C Zamboni; Clinton F Stewart; Pamela J Cheshire; LB Richmond; Suzan K Hanna; X Luo; CA Poquette; J P McGovren; Janet A Houghton; Peter J Houghton
Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft models.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(3):743-53.
1998: William C Zamboni; Peter J Houghton; J Thompson; Pamela J Cheshire; Suzan K Hanna; LB Richmond; X Lou; Clinton F Stewart
Altered irinotecan and SN-38 disposition after intravenous and oral administration of irinotecan in mice bearing human neuroblastoma xenografts.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(2):455-62.
1998: Kuntebommanahalli N Thimmaiah; B S Jayashree; Glen S Germain; Peter J Houghton; Julie K Horton
Characterization of 2-chloro-N10-substituted phenoxazines for reversing multidrug resistance in cancer cells.
Oncology research 1998;10(1):29-41.
1998: William C Zamboni; Peter J Houghton; R K Johnson; J L Hulstein; WR Crom; Pamela J Cheshire; Suzan K Hanna; LB Richmond; X Luo; Clinton F Stewart
Probenecid alters topotecan systemic and renal disposition by inhibiting renal tubular secretion.
The Journal of pharmacology and experimental therapeutics 1998;284(1):89-94.
1997: Chhabil Dass; Kuntebommanahalli N Thimmaiah; B S Jayashree; Peter J Houghton
Liquid secondary ionization mass spectrometry and collision-induced dissociation study of 2-chloro-N10-substituted phenoxazines.
Journal of mass spectrometry : JMS 1997;32(12):1279-89.
1997: Julie K Horton; Kuntebommanahalli N Thimmaiah; Guillermo A Altenberg; Ariel F Castro; Glen S Germain; G K Gowda; Peter J Houghton
Characterization of a novel bisacridone and comparison with PSC 833 as a potent and poorly reversible modulator of P-glycoprotein.
Molecular pharmacology 1997;52(6):948-57.
1997: W Luo; TR Sharif; Peter J Houghton; M Sharif
CGP 41251 and tamoxifen selectively inhibit mitogen-activated protein kinase activation and c-Fos phosphoprotein induction by substance P in human astrocytoma cells.
Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 1997;8(11):1225-40.
1997: GJ Brunn; Christine C Hudson; A Sekulić; J M Williams; Hajime Hosoi; Peter J Houghton; John C Lawrence; Robert T Abraham
Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin.
Science (New York, N.Y.) 1997;277(5322):99-101.
1997: J Thompson; William C Zamboni; Pamela J Cheshire; LB Richmond; X Luo; Janet A Houghton; Clinton F Stewart; Peter J Houghton
Efficacy of oral irinotecan against neuroblastoma xenografts.
Anti-cancer drugs 1997;8(4):313-22.
1997: J Thompson; William C Zamboni; Pamela J Cheshire; L Lutz; X Luo; Y Li; Janet A Houghton; Clinton F Stewart; Peter J Houghton
Efficacy of systemic administration of irinotecan against neuroblastoma xenografts.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(3):423-31.
1997: Clinton F Stewart; William C Zamboni; WR Crom; Peter J Houghton
Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in mice.
Cancer chemotherapy and pharmacology 1997;40(3):259-65.
1996: Peter J Houghton; Clinton F Stewart; William C Zamboni; J Thompson; X Luo; Mary K Danks; Janet A Houghton
Schedule-dependent efficacy of camptothecins in models of human cancer.
Annals of the New York Academy of Sciences 1996;803():188-201.
1996: William T Beck; Thomas M Grogan; Cheryl L Willman; C Cordon-Cardo; David M Parham; John Frank Kuttesch; M Andreeff; Susan E Bates; CW Berard; J M Boyett; N A Brophy; H J Broxterman; H S Chan; W S Dalton; M Dietel; A T Fojo; R D Gascoyne; D Head; Peter J Houghton; D K Srivastava; M Lehnert; CP Leith; Elisabeth Paietta; Z P Pavelic; R Weinstein
Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations.
Cancer research 1996;56(13):3010-20.
1996: Linda C Harris; Joanna S Remack; Peter J Houghton; Thomas P Brent
Wild-type p53 suppresses transcription of the human O6-methylguanine-DNA methyltransferase gene.
Cancer research 1996;56(9):2029-32.
1996: R Thulasi; P Dias; Peter J Houghton; Janet A Houghton
Alpha 2a-interferon-induced differentiation of human alveolar rhabdomyosarcoma cells: correlation with down-regulation of the insulin-like growth factor type I receptor.
Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 1996;7(4):531-41.
1996: L L Shu; Peter J Houghton
Separation of resistance to antitumor diarylsulfonylurea agents from collateral sensitivity to mitochondrial toxins.
Molecular pharmacology 1996;49(4):595-601.
1996: John Frank Kuttesch; David M Parham; X Luo; William H Meyer; L Bowman; DN Shapiro; Alberto S Pappo; William M Crist; William T Beck; Peter J Houghton
P-glycoprotein expression at diagnosis may not be a primary mechanism of therapeutic failure in childhood rhabdomyosarcoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(3):886-900.
1996: Janet A Houghton; Pamela J Cheshire; J D Hallman; L Lutz; X Luo; Y Li; Peter J Houghton
Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(1):107-18.
1996: Peter J Houghton; Janet A Houghton
Antitumor diarylsulfonylureas: novel agents with unfulfilled promise.
Investigational new drugs 1996;14(3):271-80.
1996: R L Merriman; L W Hertel; Richard M Schultz; Peter J Houghton; J A Houghton; P G Rutherford; LEE TANZER; G B Boder; G B Grindey
Comparison of the antitumor activity of gemcitabine and ara-C in a panel of human breast, colon, lung and pancreatic xenograft models.
Investigational new drugs 1996;14(3):243-7.
1996: Clinton F Stewart; William C Zamboni; W R Crom; Amar Gajjar; Richard L Heideman; Wayne L Furman; William H Meyer; Peter J Houghton; Charles B Pratt
Topoisomerase I interactive drugs in children with cancer.
Investigational new drugs 1996;14(1):37-47.
1995: Linda C Harris; U K Marathi; C C Edwards; Peter J Houghton; D K Srivastava; E F Vanin; B P Sorrentino; Thomas P Brent
Retroviral transfer of a bacterial alkyltransferase gene into murine bone marrow protects against chloroethylnitrosourea cytotoxicity.
Clinical cancer research : an official journal of the American Association for Cancer Research 1995;1(11):1359-68.
1995: Peter J Houghton; Pamela J Cheshire; L Myers; L Lutz; J Toth; G B Grindey; Janet A Houghton
Efficacy of sulofenur and a second generation diarylsulfonylurea, N-[5-(2,3-dihydrobenzofuryl)sulfonyl]-N'-(3,4-dichlorophenyl)urea (LY295501), against colon adenocarcinoma xenografts.
Anti-cancer drugs 1995;6(2):317-23.
1995: Randy M Wadkins; Peter J Houghton
Kinetics of transport of dialkyloxacarbocyanines in multidrug-resistant cell lines overexpressing P-glycoprotein: interrelationship of dye alkyl chain length, cellular flux, and drug resistance.
Biochemistry 1995;34(11):3858-72.
1995: Peter J Houghton; J Sosinski; J H Thakar; G B Boder; G B Grindey
Characterization of the intracellular distribution and binding in human adenocarcinoma cells of N-(4-azidophenylsulfonyl)-N'-(4-chlorophenyl)urea (LY219703), a photoaffinity analogue of the antitumor diarylsulfonylurea sulofenur.
Biochemical pharmacology 1995;49(5):661-8.
1995: WA Wesche; C D Fletcher; P Dias; Peter J Houghton; David M Parham
Immunohistochemistry of MyoD1 in adult pleomorphic soft tissue sarcomas.
The American journal of surgical pathology 1995;19(3):261-9.
1995: Peter J Houghton; Pamela J Cheshire; J D Hallman; Janet A Houghton
Therapeutic efficacy of the cyclopropylpyrroloindole, carzelesin, against xenografts derived from adult and childhood solid tumors.
Cancer chemotherapy and pharmacology 1995;36(1):45-52.
1995: Peter J Houghton; Pamela J Cheshire; J D Hallman; L Lutz; H S Friedman; Mary K Danks; Janet A Houghton
Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors.
Cancer chemotherapy and pharmacology 1995;36(5):393-403.
1994: Janet A Houghton; FG Harwood; Peter J Houghton
Cell cycle control processes determine cytostasis or cytotoxicity in thymineless death of colon cancer cells.
Cancer research 1994;54(18):4967-73.
1994: J Sosinski; J H Thakar; G S Germain; P Dias; F C Harwood; John Frank Kuttesch; Peter J Houghton
Cross-resistance to antitumor diarylsulfonylureas and collateral sensitivity to mitochondrial toxins in a human cell line selected for resistance to the antitumor agent N-(5-indanylsulfonyl)-N'-(4-chlorophenyl)urea.
Molecular pharmacology 1994;45(5):962-70.
1994: Chhabil Dass; Kuntebommanahalli N Thimmaiah; B S Jayashree; R Seshadri; Mervyn Israel; Peter J Houghton
Analysis of phenoxazine chemosensitizers: an electron ionization and keV-ion beam bombardment mass spectrometry study.
Biological mass spectrometry 1994;23(3):140-6.
1994: Michael B Dilling; P Dias; DN Shapiro; G S Germain; R K Johnson; Peter J Houghton
Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin-like growth factor receptor.
Cancer research 1994;54(4):903-7.
1994: Peter J Houghton; Pamela J Cheshire; J C Hallman; J L Gross; R J McRipley; J H Sun; C H Behrens; D L Dexter; Janet A Houghton
Evaluation of a novel bis-naphthalimide anticancer agent, DMP 840, against human xenografts derived from adult, juvenile, and pediatric cancers.
Cancer chemotherapy and pharmacology 1994;33(4):265-72.
1993: Randy M Wadkins; Peter J Houghton
The role of drug-lipid interactions in the biological activity of modulators of multi-drug resistance.
Biochimica et biophysica acta 1993;1153(2):225-36.
1993: Julie K Horton; Kuntebommanahalli N Thimmaiah; F C Harwood; John Frank Kuttesch; Peter J Houghton
Pharmacological characterization of N-substituted phenoxazines directed toward reversing Vinca alkaloid resistance in multidrug-resistant cancer cells.
Molecular pharmacology 1993;44(3):552-9.
1993: Peter J Houghton; Pamela J Cheshire; J C Hallman; M C Bissery; A Mathieu-Boué; Janet A Houghton
Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin.
Cancer research 1993;53(12):2823-9.
1993: J Sosinski; J H Thakar; G S Germain; F C Harwood; Peter J Houghton
Proliferation-dependent and -independent cytotoxicity by antitumor diarylsulfonylureas. Indication of multiple mechanisms of drug action.
Biochemical pharmacology 1993;45(10):2135-42.
1993: R M Wadkins; Peter J Houghton
Kinetics of cellular permeability of phenoxazine and its dependence on P-glycoprotein expression.
FEBS letters 1993;322(1):1-5.
1993: Janet A Houghton; D A Adkins; Peter J Houghton
Enhanced cytotoxicity of 5-fluorouracil combined with [6RS]leucovorin and recombinant human interferon-alpha 2a in colon carcinoma cells.
Advances in experimental medicine and biology 1993;339():133-42; discussion 165-7.
1992: P Dias; David M Parham; DN Shapiro; S J Tapscott; Peter J Houghton
Monoclonal antibodies to the myogenic regulatory protein MyoD1: epitope mapping and diagnostic utility.
Cancer research 1992;52(23):6431-9.
1992: Kuntebommanahalli N Thimmaiah; Julie K Horton; R Seshadri; Mervyn Israel; Janet A Houghton; F C Harwood; Peter J Houghton
Synthesis and chemical characterization of N-substituted phenoxazines directed toward reversing vinca alkaloid resistance in multidrug-resistant cancer cells.
Journal of medicinal chemistry 1992;35(18):3358-64.
1992: U Gündüz; M S Elliott; Peter Seubert; J A Houghton; Peter J Houghton; R W Trewyn; J R Katze
Absence of tRNA-guanine transglycosylase in a human colon adenocarcinoma cell line.
Biochimica et biophysica acta 1992;1139(3):229-38.
1992: Peter J Houghton; A Rahman; C L Will; Bruce J Dolnick; Janet A Houghton
Mutation(s) of the thymidylate synthase gene of human adenocarcinoma cells causes a thymidylate synthase-negative phenotype that can be attenuated by exogenous folates.
Cancer research 1992;52(3):558-65.
1992: Peter J Houghton; Pamela J Cheshire; L Myers; Clinton F Stewart; Timothy W Synold; Janet A Houghton
Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors.
Cancer chemotherapy and pharmacology 1992;31(3):229-39.
1992: Janet A Houghton; L G Williams; S K Loftin; Pamela J Cheshire; Christopher L Morton; Peter J Houghton; A Dayan; Jacques Jolivet
Factors that influence the therapeutic activity of 5-fluorouracil [6RS]leucovorin combinations in colon adenocarcinoma xenografts.
Cancer chemotherapy and pharmacology 1992;30(6):423-32.
1991: J H Thakar; C Chapin; R H Berg; R A Ashmun; Peter J Houghton
Effect of antitumor diarylsulfonylureas on in vivo and in vitro mitochondrial structure and functions.
Cancer research 1991;51(23 Pt 1):6286-91.
1991: Janet A Houghton; D A Adkins; A Rahman; Peter J Houghton
Interaction between 5-fluorouracil, [6RS]leucovorin, and recombinant human interferon-alpha 2a in cultured colon adenocarcinoma cells.
Cancer communications 1991;3(7):225-31.
1991: Peter J Houghton; DN Shapiro; Janet A Houghton
Rhabdomyosarcoma. From the laboratory to the clinic.
Pediatric clinics of North America 1991;38(2):349-64.
1991: J Sosinski; C Chapin; J H Thakar; Peter J Houghton
Influence of extracellular pH on the accumulation and cytotoxicity of N-(4-methylphenylsulfonyl)-N'-(4-chlorophenyl)urea in human cell lines.
Cancer communications 1991;3(12):373-81.
1990: P Dias; David M Parham; DN Shapiro; B L Webber; Peter J Houghton
Myogenic regulatory protein (MyoD1) expression in childhood solid tumors: diagnostic utility in rhabdomyosarcoma.
The American journal of pathology 1990;137(6):1283-91.
1990: DN Shapiro; Peter J Houghton; B J Hazelton; G S Germain; K G Murti; A Rahman; Janet A Houghton
Morphological and molecular characterization of spontaneous myogenic differentiation in a human rhabdomyosarcoma cell line.
Cancer research 1990;50(18):6002-9.
1990: E C Douglass; M Valentine; ST Rowe; David M Parham; Judith A Wilimas; J M Sanders; Peter J Houghton
Malignant rhabdoid tumor: a highly malignant childhood tumor with minimal karyotypic changes.
Genes, chromosomes & cancer 1990;2(3):210-6.
1990: Janet A Houghton; L G Williams; Pamela J Cheshire; irving william wainer; P Jadaud; Peter J Houghton
Influence of dose of [6RS]leucovorin on reduced folate pools and 5-fluorouracil-mediated thymidylate synthase inhibition in human colon adenocarcinoma xenografts.
Cancer research 1990;50(13):3940-6.
1990: Janet A Houghton; L G Williams; Siebold S N de Graaf; Pamela J Cheshire; John H Rodman; Daniel Maneval; irving william wainer; P Jadaud; Peter J Houghton
Relationship between dose rate of [6RS]Leucovorin administration, plasma concentrations of reduced folates, and pools of 5,10-methylenetetrahydrofolates and tetrahydrofolates in human colon adenocarcinoma xenografts.
Cancer research 1990;50(12):3493-502.
1990: S Radparvar; Peter J Houghton; G Germain; J Pennington; A Rahman; Janet A Houghton
Cellular pharmacology of 5-fluorouracil in a human colon adenocarcinoma cell line selected for thymidine kinase deficiency.
Biochemical pharmacology 1990;39(11):1759-65.
1990: Douglas R Strother; David M Parham; Peter J Houghton
Expression of the 5.1 H11 antigen, a fetal muscle surface antigen, in normal and neoplastic tissue.
Archives of pathology & laboratory medicine 1990;114(6):593-6.
1990: W H Meyer; J A Houghton; Peter J Houghton; B L Webber; E C Douglass; A Thomas Look
Development and characterization of pediatric osteosarcoma xenografts.
Cancer research 1990;50(9):2781-5.
1990: Peter J Houghton; F C Bailey; G S Germain; G B Grindey; J J Howbert; Janet A Houghton
Studies on the cellular pharmacology of N-(4-methylphenylsulfonyl)-N'-(4-chlorophenyl)-urea.
Biochemical pharmacology 1990;39(7):1187-92.
1990: Peter J Houghton; F C Bailey; Janet A Houghton; K G Murti; J J Howbert; G B Grindey
Evidence for mitochondrial localization of N-(4-methylphenylsulfonyl)-N'-(4-chlorophenyl)urea in human colon adenocarcinoma cells.
Cancer research 1990;50(3):664-8.
1990: Peter J Houghton; F C Bailey; G S Germain; G B Grindey; B C Witt; Janet A Houghton
N-(5-indanylsulfonyl)-N'-(4-chlorophenyl)urea, a novel agent equally cytotoxic to nonproliferating human colon adenocarcinoma cells.
Cancer research 1990;50(2):318-22.
1990: Kuntebommanahalli N Thimmaiah; Julie K Horton; X D Qian; William T Beck; Janet A Houghton; Peter J Houghton
Structural determinants of phenoxazine type compounds required to modulate the accumulation of vinblastine and vincristine in multidrug-resistant cell lines.
Cancer communications 1990;2(7):249-59.
1990: W H Meyer; S K Loftin; J A Houghton; Peter J Houghton
Accumulation, intracellular metabolism, and antitumor activity of high- and low-dose methotrexate in human osteosarcoma xenografts.
Cancer communications 1990;2(6):219-29.
1989: Peter J Houghton; J Mirro; R M Goorha; S C Raimondi; A Fridland; Janet A Houghton
Growth and differentiation of a human T-cell leukemia cell line, CCRF-CEM, grafted in mice.
Cancer research 1989;49(24 Pt 1):7124-31.
1989: W M Roberts; E C Douglass; Stephen Peiper; Peter J Houghton; A Thomas Look
Amplification of the gli gene in childhood sarcomas.
Cancer research 1989;49(19):5407-13.
1989: Julie K Horton; Kuntebommanahalli N Thimmaiah; Janet A Houghton; M E Horowitz; Peter J Houghton
Modulation by verapamil of vincristine pharmacokinetics and toxicity in mice bearing human tumor xenografts.
Biochemical pharmacology 1989;38(11):1727-36.
1989: Peter J Houghton; G S Germain; B J Hazelton; J W Pennington; Janet A Houghton
Mutants of human colon adenocarcinoma, selected for thymidylate synthase deficiency.
Proceedings of the National Academy of Sciences of the United States of America 1989;86(4):1377-81.
1989: S Radparvar; Peter J Houghton; Janet A Houghton
Effect of polyglutamylation of 5,10-methylenetetrahydrofolate on the binding of 5-fluoro-2'-deoxyuridylate to thymidylate synthase purified from a human colon adenocarcinoma xenograft.
Biochemical pharmacology 1989;38(2):335-42.
1989: Janet A Houghton; L G Williams; Siebold S N de Graaf; Pamela J Cheshire; irving william wainer; P Jadaud; Peter J Houghton
Comparison of the conversion of 5-formyltetrahydrofolate and 5-methyltetrahydrofolate to 5,10-methylenetetrahydrofolates and tetrahydrofolates in human colon tumors.
Cancer communications 1989;1(3):167-74.
1989: William H Meyer; Peter J Houghton; M E Horowitz; E Etcubanas; Charles B Pratt; F A Hayes; Elizabeth Thompson; A A Green; J A Houghton; John T Sandlund
Use of investigational drugs as initial therapy for childhood solid tumors.
Haematology and blood transfusion 1989;32():141-8.
1989: Peter J Houghton; Janet A Houghton; L Myers; Pamela J Cheshire; J J Howbert; G B Grindey
Evaluation of N-(5-indanylsulfonyl)-N'-(4-chlorophenyl)-urea against xenografts of pediatric rhabdomyosarcoma.
Cancer chemotherapy and pharmacology 1989;25(2):84-8.
1988: Julie K Horton; Peter J Houghton; Janet A Houghton
Relationships between tumor responsiveness, vincristine pharmacokinetics and arrest of mitosis in human tumor xenografts.
Biochemical pharmacology 1988;37(20):3995-4000.
1988: Janet A Houghton; L G Williams; S Radparvar; Peter J Houghton
Characterization of the pools of 5,10-methylenetetrahydrofolates and tetrahydrofolates in xenografts of human colon adenocarcinoma.
Cancer research 1988;48(11):3062-9.
1988: M E Horowitz; E Etcubanas; M L Christensen; J A Houghton; S L George; A A Green; Peter J Houghton
Phase II testing of melphalan in children with newly diagnosed rhabdomyosarcoma: a model for anticancer drug development.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1988;6(2):308-14.
1988: Peter J Houghton; R Tharp; J A Houghton; J F Holland; J G Bekesi
Evaluation of 3-(p-fluorophenyl)-L-alanyl-3-[m-bis-(2-chloroethyl) aminophenyl]-L-alanyl-L-methionine ethyl ester HCl (PTT.119) against xenografts of human rhabdomyosarcoma.
Cancer chemotherapy and pharmacology 1988;22(3):201-4.
1988: S Radparvar; Peter J Houghton; J A Houghton
Characteristics of thymidylate synthase purified from a human colon adenocarcinoma.
Archives of biochemistry and biophysics 1988;260(1):342-50.
1988: Janet A Houghton; L G Williams; S S deGraaf; S Radparvar; irving william wainer; J R Rodman; Peter J Houghton
Selectivity of CF and 5-fluorouracil: critical role of polyglutamylation.
Advances in experimental medicine and biology 1988;244():85-95.
1987: Janet A Houghton; S Radparvar; P M Torrance; L G Williams; Peter J Houghton
Determination of thymidylate synthase activity in colon tumor tissues after treatment with 5-fluorouracil.
Biochemical pharmacology 1987;36(8):1285-9.
1987: E C Douglass; M Valentine; E Etcubanas; David M Parham; B L Webber; Peter J Houghton; J A Houghton; A A Green
A specific chromosomal abnormality in rhabdomyosarcoma.
Cytogenetics and cell genetics 1987;45(3-4):148-55.
1986: Janet A Houghton; K D Weiss; L G Williams; P M Torrance; Peter J Houghton
Relationship between 5-fluoro-2'-deoxyuridylate, 2'-deoxyuridylate, and thymidylate synthase activity subsequent to 5-fluorouracil administration, in xenografts of human colon adenocarcinomas.
Biochemical pharmacology 1986;35(8):1351-8.
1986: Janet A Houghton; P M Torrance; S Radparvar; L G Williams; Peter J Houghton
Binding of 5-fluorodeoxyuridylate to thymidylate synthase in human colon adenocarcinoma xenografts.
European journal of cancer & clinical oncology 1986;22(4):505-10.
1984: Janet A Houghton; L G Williams; P M Torrance; Peter J Houghton
Determinants of intrinsic sensitivity to Vinca alkaloids in xenografts of pediatric rhabdomyosarcomas.
Cancer research 1984;44(2):582-90.